Eli Lilly Reports Phase 2 Data for Axicabtagene ciloleucel in Heart failure

Eli Lilly today announced Phase 2 results for axicabtagene ciloleucel in patients with heart failure. The study demonstrated that axicabtagene ciloleucel achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of heart failure and support the continued development of axicabtagene ciloleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.